2024
Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies A World Health Organization Pharmacovigilance Study
Yang J, Jung S, Kim M, Lee S, Yon D, Shin J, Lee J. Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies A World Health Organization Pharmacovigilance Study. Ophthalmology 2024, 132: 62-78. PMID: 39004231, DOI: 10.1016/j.ophtha.2024.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabCardiovascular DiseasesCerebrovascular DisordersDatabases, FactualFemaleHumansIntravitreal InjectionsMaleMiddle AgedOdds RatioPharmacovigilanceRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AWorld Health OrganizationConceptsIntravitreal anti-VEGF treatmentAdverse drug reactionsAnti-VEGF treatmentAnti-VEGFAtrial fibrillationIntravitreal anti-VEGF therapyCerebral hemorrhageIndividual case safety reportsInter-drugReports of myocardial infarctionMyocardial infarctionDisproportionate Bayesian reportingIntravitreal anti-VEGFAnti-VEGF therapyCarotid artery stenosisIncreasing reportsHypertensive crisisCase-noncase studySupraventricular tachycardiaAtrial flutterSubarachnoid hemorrhageIntravitrealArtery stenosisAngina pectorisOdds ratioCost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.Peer-Reviewed Original ResearchIncremental net monetary benefitHereditary hemorrhagic telangiectasiaStandard-of-careBevacizumab therapyWillingness-to-payNet monetary benefitHemorrhagic telangiectasiaWillingness-to-pay thresholdsStandard-of-care strategiesCare of patientsCost-effectiveness analysisAnti-VEGF bevacizumabSystemic antiangiogenic therapyCurrent standard-of-careMonetary benefitsTime horizonFormulary placementHealthcare resource utilizationStandard of careLifetime time horizonPatient quality-of-lifeScenario analysisProbabilistic sensitivity analysesIV bevacizumabAnti-VEGFMolecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).
Zaemes J, Hugaboom M, Shah V, Haas N, McDermott D, Jegede O, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Hurwitz M, Wu C, Einstein D, Hammers H, Signoretti S, West D, Denize T, Atkins M, Braun D. Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC). Journal Of Clinical Oncology 2024, 42: 4546-4546. DOI: 10.1200/jco.2024.42.16_suppl.4546.Peer-Reviewed Original ResearchObjective response rateImmune checkpoint blockadeProgression-free survivalProgressive diseaseAnti-VEGFOverall survivalAssociated with higher progression-free survivalTumor samplesAdvanced clear cell renal cell carcinomaCombined immune checkpoint blockadeHigher progression-free survivalIncreased PFSImmune checkpoint blockade therapyShorter progression-free survivalClear cell renal cell carcinomaAnti-VEGF therapyCell renal cell carcinomaWeeks of therapyRenal cell carcinomaBiomarkers of efficacyFFPE tumor samplesNIVO monotherapyCheckpoint blockadeDecreased OSProspective trialsCombining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)
Hochster H, Catalano P, Weitz M, Mitchell E, Cohen D, O’Dwyer P, Faller B, Kortmansky J, O’Hara M, Kricher S, Lacy J, Lenz H, Verma U, Benson A. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). Journal Of The National Cancer Institute 2024, 116: 1487-1494. PMID: 38775718, PMCID: PMC11378308, DOI: 10.1093/jnci/djae114.Peer-Reviewed Original ResearchProgression-free survivalDisease-control ratePhase 3 trialColorectal cancerAnti-VEGFAnti-VEGFRAnti-EGFRKRAS-wild type colorectal cancerPhase II study of irinotecanKRAS wild-type colorectal cancerMedian progression-free survivalRandomized phase II studyKRAS wild-type tumorsWild-type colorectal cancerAnti-VEGFR antibodiesAnti-VEGF drugsTreated with ICSecond-line treatmentStudy of irinotecanWild-type tumorsAdvanced colorectal cancerPhase 2 studyAnti-EGFR antibodiesAnti-VEGF antibodyECOG PSEmerging Co‐Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization
Shen J, Chen L, Lv X, Liu N, Miao Y, Zhang Q, Xiao Z, Li M, Yang Y, Liu Z, Chen Q. Emerging Co‐Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization. Advanced Materials 2024, 36: e2314095. PMID: 38344832, DOI: 10.1002/adma.202314095.Peer-Reviewed Original ResearchAge-related macular degenerationAnti-VEGFIntravitreal injectionAssociated with sight-threatening complicationsAnti-vascular endothelial growth factorAge-related macular degeneration treatmentFrequent intravitreal injectionsSight-threatening complicationsChoroidal neovascularization modelEndothelial growth factorInhibitor of angiogenesisChoroidal neovascularizationSubconjunctival injectionSubconjunctival administrationMacular degenerationNeovascularization modelImprove patient outcomesTherapeutic resultsEye conditionsInhibit angiogenesisQuality of lifeMultitarget therapyGrowth factorRabbit eyeballPatient outcomes
2023
Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments anti-tumor activity in melanoma
Tran T, Caulfield J, Zhang L, Schoenfeld D, Djureinovic D, Chiang V, Oria V, Weiss S, Olino K, Jilaveanu L, Kluger H. Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments anti-tumor activity in melanoma. JCI Insight 2023, 8: e157347. PMID: 36821392, PMCID: PMC10132152, DOI: 10.1172/jci.insight.157347.Peer-Reviewed Original ResearchConceptsTumor microenvironmentAnti-VEGFCytokine/chemokine signalingCytokine/chemokine profilingBlood-brain barrier modelBlood vesselsLeukocyte transmigrationTumor-associated blood vesselsTumor-associated macrophagesIntratumoral blood vesselsAnti-angiogenesis effectAnti-tumor activityExtracranial diseasePlasmacytoid DCsImmune checkpointsPD-1Melanoma murine modelImmune infiltrationBBB modelChemokine profilingEndothelial stabilizationMurine modelLenvatinibCombined targetingMelanoma modelOutcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Takemura K, Lemelin A, Ernst M, Wells C, Basappa N, Szabados B, Powles T, Davis I, Wood L, Kapoor A, McKay R, Lee J, Meza L, Pal S, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Choueiri T, Heng D. Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2023, 41: 600-600. DOI: 10.1200/jco.2023.41.6_suppl.600.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumFirst-line therapyRenal cell carcinomaAssociated with longer OSAnti-VEGF monotherapyAnti-VEGFBrain metastasesOutcomes of patientsBaseline patient characteristicsStable diseaseComplete responsePartial responseOverall survivalCombination therapyStereotactic radiosurgeryLonger OSLocal therapyPatient characteristicsInitiation of first-line therapyBest overall responseWhole-brain radiotherapyCohort of patientsProportion of patientsCell carcinomaDisease sites
2021
Subretinal Hyperreflective Material (SHRM) as biomarker of activity in Exudative and Non- exudative inflammatory choroidal neovascularization
Arora A, Agarwal A, Bansal R, Katoch D, Marchese A, Aggarwal K, Agrawal R, Gupta V. Subretinal Hyperreflective Material (SHRM) as biomarker of activity in Exudative and Non- exudative inflammatory choroidal neovascularization. Ocular Immunology And Inflammation 2021, 31: 48-55. PMID: 34648411, DOI: 10.1080/09273948.2021.1980813.Peer-Reviewed Original ResearchConceptsSubretinal hyperreflective materialSS-OCT angiographyInflammatory choroidal neovascularizationSS-OCTHyperreflective materialChoroidal neovascularizationIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factorSwept-source optical coherence tomographyBiomarkers of activityResponse to therapyEndothelial growth factorOptical coherence tomographyI-CNVPosterior uveitisAnti-VEGFTherapeutic responseIRF/SRFCoherence tomographyFollow-upNo treatmentGrowth factorBCVAEyesIntervention studies
2018
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology 2018, 126: 1007-1015. PMID: 30292542, DOI: 10.1016/j.ophtha.2018.09.040.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaRoutine clinical practiceSystemic serious adverse eventsMacular laserMajor bleedingCerebrovascular diseaseMyocardial infarctionClinical practiceCause hospitalizationAdverse eventsHazard ratioIntravitreal corticosteroidsAnti-VEGFMacular edemaDME treatmentTreatment of DMEIntravitreal anti-VEGF therapyCox proportional hazards regressionAnti-VEGF pharmacotherapySystemic safety profileCorticosteroid-treated patientsRetrospective cohort studySerious adverse eventsSystemic adverse eventsMacular laser photocoagulation
2014
Current Perspectives in the Management of Retinopathy of Prematurity
Dogra M, Katoch D. Current Perspectives in the Management of Retinopathy of Prematurity. Delhi Journal Of Ophthalmology 2014, 25: 108-117. DOI: 10.7869/djo.90.Peer-Reviewed Original ResearchNational Neonatology ForumLaser photocoagulationPremature babiesManagement of retinopathy of prematurityConfluent laser treatmentLens sparing vitrectomyPrevention of ROPTreatment of ROPAnti-VEGF therapyDiode laser photocoagulationRetinopathy of prematurityHigh birth weightStandard of careTreatable ROPSevere ROPAnti-VEGFMature babiesRescue therapyNational Neonatology Forum of IndiaChildhood blindnessBirth weightOxygen saturation levelsScreening programLaser treatmentPhotocoagulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply